|
Bruce Shook
Serial MedTech Entrepreneur, Vice Chair of the Board
Life Sciences PA
King of Prussia, PA
USA
|
Bruce Shook is a serial medical technology entrepreneur with 40 years of industry experience, including multiple early stage ventures focused on opportunities in cardiac surgery, cardiology, neurosurgery, psychiatry and vascular disease. Mr. Shook formed Vesper Medical in 2016 as a spinout of Intact Vascular. Mr. Shook served as President & CEO of both Intact Vascular and Vesper Medical until Intact Vascular was purchased by Royal Philips in 2020 and Vesper Medical was acquired by Royal Philips in 2022. Prior to Vesper Medical and Intact Vascular, Mr. Shook was co-founder, Director, President and CEO of Neuronetics [NASDAQ: STIM], which markets a non-invasive brain stimulation technology for the treatment of depression and OCD.
Previously, Mr. Shook was co-founder, Director, President and CEO at Neuron Therapeutics, a venture-backed company developing a drug/device product for the treatment of CNS disorders and President of Abiomed [NASDAQ: ABMD] where he successfully obtained PMA approval for the first, FDA-approved ventricular assist device. Mr. Shook also developed cardiac pacing and anti-arrhythmia products at Cordis Corporation. He has raised more than $500 million in private equity funding across multiple ventures.
Mr. Shook has served on several corporate boards including Devoro Medical (acquired by Boston Scientific), Surgiquest (acquired by Conmed), Respicardia (acquired by Zoll) and CoTherix (acquired by Actelion). Mr. Shook currently serves as a Director for Evident Vascular, Inquis Medical and Protexa Endovascular; and serves as Vice Chair on the Life Sciences PA and the Penn State Research Foundation boards, respectively.
Mr. Shook holds advanced degrees in Biomedical Engineering and Business Administration from Columbia University and the MIT Sloan School of Management, respectively. He earned a B.S. degree in Chemical Engineering from Penn State University.
Previously, Mr. Shook was co-founder, Director, President and CEO at Neuron Therapeutics, a venture-backed company developing a drug/device product for the treatment of CNS disorders and President of Abiomed [NASDAQ: ABMD] where he successfully obtained PMA approval for the first, FDA-approved ventricular assist device. Mr. Shook also developed cardiac pacing and anti-arrhythmia products at Cordis Corporation. He has raised more than $500 million in private equity funding across multiple ventures.
Mr. Shook has served on several corporate boards including Devoro Medical (acquired by Boston Scientific), Surgiquest (acquired by Conmed), Respicardia (acquired by Zoll) and CoTherix (acquired by Actelion). Mr. Shook currently serves as a Director for Evident Vascular, Inquis Medical and Protexa Endovascular; and serves as Vice Chair on the Life Sciences PA and the Penn State Research Foundation boards, respectively.
Mr. Shook holds advanced degrees in Biomedical Engineering and Business Administration from Columbia University and the MIT Sloan School of Management, respectively. He earned a B.S. degree in Chemical Engineering from Penn State University.